Clinical Trials Browser

Phase 2 × Recruiting × Waldenstrom Macroglobulinemia × Clear all

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04728893 2026-03-16

MK-1026-003

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT07387471 2026-03-16

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT06510491 2026-03-13

Epcoritamab in Previously Treated WM

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT06986174 2025-12-05

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Phase 2 Recruiting

Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05099471 2025-11-28

VIWA-1

Phase 2 Recruiting

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT06561347 2025-11-24

ZEBRA

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT07231952 2025-11-17

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05190705 2025-05-23

Loncastuximab Tesirine in WM

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT05734495 2025-05-11

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Phase 2 Recruiting

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05914662 2024-08-28

ZBR

Phase 2 Recruiting

Waldenstrom Macroglobulinemia

NCT03697356 2023-10-06

Ballondor

Phase 2 Recruiting

Waldenstrom Macroglobulinemia